Home » Stocks » Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc. (LCTX)

Stock Price: $0.860 USD 0.010 (1.18%)
Updated Aug 4, 2020 12:01 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 128.85M
Revenue (ttm) 3.10M
Net Income (ttm) -59.42M
Shares Out 149.82M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $0.860
Previous Close $0.850
Change ($) 0.010
Change (%) 1.18%
Day's Open 0.853
Day's Range 0.840 - 0.867
Day's Volume 431,410
52-Week Range 0.534 - 1.670

More Stats

Market Cap 128.85M
Enterprise Value 83.92M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 149.82M
Float 107.50M
EPS (basic) -0.4
EPS (diluted) -0.37
FCF / Share -0.19
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.41M
Short Ratio 3.32
Short % of Float 4.99%
Beta 2.15
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 41.55
PB Ratio 1.19
Revenue 3.10M
Operating Income -33.55M
Net Income -59.42M
Free Cash Flow -27.86M
Net Cash 44.93M
Net Cash / Share 0.30
Gross Margin 100.06%
Operating Margin -1,082.01%
Profit Margin -1,916.10%
FCF Margin -898.36%
ROA -12.99%
ROE -44.78%
ROIC -101.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.08*
(490.70% upside)
Low
3.00
Current: $0.860
High
7.00
Target: 5.08
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3.524.993.465.927.045.244.433.924.433.71
Revenue Growth-29.53%44.25%-41.62%-15.82%34.17%18.27%13.25%-11.7%19.58%-
Gross Profit3.104.693.295.575.934.413.643.484.353.68
Operating Income-38.88-41.80-38.90-58.97-65.81-50.68-55.99-25.32-18.69-9.85
Net Income-11.71-45.99-19.9833.57-46.99-36.41-43.88-21.43-16.52-11.18
Shares Outstanding14612711497.3279.7166.4754.2349.2147.0540.27
Earnings Per Share-0.08-0.36-0.170.34-0.59-0.55-0.81-0.44-0.35-0.28
Operating Cash Flow-31.95-30.88-30.52-42.33-44.54-38.85-29.51-19.68-13.59-7.73
Capital Expenditures-0.36-1.42-1.13-2.53-5.33-0.69-2.25-0.40-0.96-0.21
Free Cash Flow-32.31-32.30-31.64-44.85-49.88-39.55-31.76-20.08-14.55-7.95
Cash & Equivalents54.3330.7438.1822.7242.9829.495.624.4122.2733.38
Total Debt5.172.271.533.985.100.53----
Net Cash / Debt49.1628.4836.6418.7337.8828.965.624.4122.2733.38
Assets12510217314394.6674.9057.7329.7545.8353.27
Liabilities14.239.418.9812.0618.2112.1815.475.454.373.85
Book Value11393.8416311825.8236.4614.809.5828.6538.17
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Lineage Cell Therapeutics, Inc.
Country United States
Employees 50
CEO Brian M. Culley

Stock Information

Ticker Symbol LCTX
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: LCTX

Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.